分别通过对DC2．4细胞白介素-12（IL-12）和IL-10的ELISA检测，蛋白酶激活受体（PAR-2）的基因表达和丝裂原活化蛋白酶（MAPK）p44／42的磷酸化来观察Der f I对DC2．4细胞的作用及其诱发哮喘机制的初步研究。Der f I作用于DC2．4细胞的...分别通过对DC2．4细胞白介素-12（IL-12）和IL-10的ELISA检测，蛋白酶激活受体（PAR-2）的基因表达和丝裂原活化蛋白酶（MAPK）p44／42的磷酸化来观察Der f I对DC2．4细胞的作用及其诱发哮喘机制的初步研究。Der f I作用于DC2．4细胞的结果显示，Der f I可促进DC2．4细胞IL-10的分泌（P〈0．01），抑制IL-12的分泌（P〈0．05），但信号通路抑制剂U0126可以逆转细胞因子的分泌模式；促进磷酸化p44／42MAPK的表达（尤其是促进p42的磷酸化）；抑制PAR．2受体的表达并呈时间依赖性。Th1／Th2失衡及Th2细胞功能亢进是过敏性哮喘的免疫基础，3312型免疫应答可能是哮喘发生的机制之一。本研究中由于Der f I作用于DC2．4细胞后抑制初始T细胞向Th1细胞分化而促使其向Th2细胞分化从而促使Th2型免疫应答，进而诱发过敏性哮喘，信号通路p44142MAPK的磷酸化加强和PAR-2受体表达的抑制也在诱发过敏性哮喘过程中起到促进作用。展开更多
Objective To review the update research progress about the treatment of diabetic macular edema and to give helpful guidelines in the treatment of diabetic macular edema based on available evidence to date. Data source...Objective To review the update research progress about the treatment of diabetic macular edema and to give helpful guidelines in the treatment of diabetic macular edema based on available evidence to date. Data sources A literature search of all English articles was performed on the online electronic PubMed database dated 1984 to 2009. The keywords searched included： macular edema, therapy, laser coagulation, intravitreal triamcinolone acetonide, vascular endothelial growth factor inhibitor, protein kinase C inhibitor and Pars plana vitrectomy. After finding relevant articles within these search limits, a manual search was conducted through the references from these articles. Study selection Original articles and critical reviews were reviewed and selected to address the stated purpose. Results To date, demonstrated means to reduce the risk of vision loss from diabetic macular edema include focal/grid laser photocoagulation and improved metabolic control. Emerging pharmacologic therapies （intravitreal triamcinolone acetonide, vascular endothelial growth factor inhibitors and protein kinase C beta-isoform inhibitors） and Pars plana vitrectomy have shown early promise in the treatment of diabetic macular edema. Conclusions As there has been extensive development in multiple treatments of diabetic macular edema, choice of the most suitable treatment for specific patients becomes important. Combination therapy of laser, pharmacological and surqical treatment modalities mav offer an alternative to treatment of diabetic macular edema.展开更多
文摘分别通过对DC2．4细胞白介素-12（IL-12）和IL-10的ELISA检测，蛋白酶激活受体（PAR-2）的基因表达和丝裂原活化蛋白酶（MAPK）p44／42的磷酸化来观察Der f I对DC2．4细胞的作用及其诱发哮喘机制的初步研究。Der f I作用于DC2．4细胞的结果显示，Der f I可促进DC2．4细胞IL-10的分泌（P〈0．01），抑制IL-12的分泌（P〈0．05），但信号通路抑制剂U0126可以逆转细胞因子的分泌模式；促进磷酸化p44／42MAPK的表达（尤其是促进p42的磷酸化）；抑制PAR．2受体的表达并呈时间依赖性。Th1／Th2失衡及Th2细胞功能亢进是过敏性哮喘的免疫基础，3312型免疫应答可能是哮喘发生的机制之一。本研究中由于Der f I作用于DC2．4细胞后抑制初始T细胞向Th1细胞分化而促使其向Th2细胞分化从而促使Th2型免疫应答，进而诱发过敏性哮喘，信号通路p44142MAPK的磷酸化加强和PAR-2受体表达的抑制也在诱发过敏性哮喘过程中起到促进作用。
文摘Objective To review the update research progress about the treatment of diabetic macular edema and to give helpful guidelines in the treatment of diabetic macular edema based on available evidence to date. Data sources A literature search of all English articles was performed on the online electronic PubMed database dated 1984 to 2009. The keywords searched included： macular edema, therapy, laser coagulation, intravitreal triamcinolone acetonide, vascular endothelial growth factor inhibitor, protein kinase C inhibitor and Pars plana vitrectomy. After finding relevant articles within these search limits, a manual search was conducted through the references from these articles. Study selection Original articles and critical reviews were reviewed and selected to address the stated purpose. Results To date, demonstrated means to reduce the risk of vision loss from diabetic macular edema include focal/grid laser photocoagulation and improved metabolic control. Emerging pharmacologic therapies （intravitreal triamcinolone acetonide, vascular endothelial growth factor inhibitors and protein kinase C beta-isoform inhibitors） and Pars plana vitrectomy have shown early promise in the treatment of diabetic macular edema. Conclusions As there has been extensive development in multiple treatments of diabetic macular edema, choice of the most suitable treatment for specific patients becomes important. Combination therapy of laser, pharmacological and surqical treatment modalities mav offer an alternative to treatment of diabetic macular edema.
